TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression - Wikidata - wikimedia - TriplyDB

TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression

TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression

http://www.wikidata.org/entity/Q36413746

about

Combinatorial treatment with polyI:C and anti-IL6 enhances apoptosis and suppresses metastasis of lung cancer cells.Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study CD14+CD15-HLA-DR- myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure.Therapeutic vaccine to cure large mouse hepatocellular carcinomas.Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen.Bufalin Suppresses Migration and Invasion of Hepatocellular Carcinoma Cells Elicited by Poly (I:C) Therapy.Targeting VEGF/VEGFR to Modulate Antitumor Immunity.Staphylococcal Enterotoxins Dose-Dependently Modulate the Generation of Myeloid-Derived Suppressor Cells Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review

P2860

Q33779298-57273012-D374-4E43-9D55-40BC52D90B37 Q37665692-534B3DD6-E53A-46FF-9D0F-7CF6F78608C1 Q40180993-9B6C3B22-E943-467E-A0F9-FF4713C9D12D Q41592594-CDA23AB8-A8A9-45E8-855C-FCC6FFDA5B67 Q42042886-718FBA17-9D4A-415C-9A3E-2D6BA29797F8 Q50423292-4FA64543-BD08-4838-8FFE-F65CC110A687 Q52856745-133C644F-E907-4382-8F2B-6CE83E7B211E Q54112790-CCF4C4A7-D548-4BDE-BC16-78DFD0808031 Q55008337-E3B617CD-D422-4FA3-B5B1-9FF81137C74B Q57075099-D8BCAB9E-8D12-4336-8896-52896507A611 Q58755253-77BA56E4-CA4C-4339-A6E0-28B796D183AC

P2860

TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression

http://www.wikidata.org/entity/Q36413746

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

TLR3 agonist and Sorafenib com ...... cellular carcinoma progression

@ast

TLR3 agonist and Sorafenib com ...... cellular carcinoma progression

@en

type

label

TLR3 agonist and Sorafenib com ...... cellular carcinoma progression

@ast

TLR3 agonist and Sorafenib com ...... cellular carcinoma progression

@en

prefLabel

TLR3 agonist and Sorafenib com ...... cellular carcinoma progression

@ast

TLR3 agonist and Sorafenib com ...... cellular carcinoma progression

@en

P1433

Q36413746-C4F8CC23-70C3-4F25-98C2-2750AFBC4C50

P1476

Q36413746-5F71B108-EE23-43E6-9F4B-094979BBA834

P2093

Q36413746-16295327-6F6F-4DBD-ADF5-61E16B8DEC72

Q36413746-531C121D-6E58-4DC6-8F45-2E4B6F8D8A72

Q36413746-5F7B0707-418C-491B-AAFD-33CFBBD7BCDE

Q36413746-62A9E6A4-2F17-4653-8B6D-00211A70903E

Q36413746-71103924-F0A7-4FA4-9A50-C43E33626E66

Q36413746-9D137080-7FDD-44E2-932D-4B7E66A98E56

Q36413746-D07AC652-6062-439B-8E51-76C67282F1F0

P2860

Q36413746-042C3F44-1FCA-4835-B25F-577C85896CB3

Q36413746-146BF32B-2F63-4D95-9037-2248A1135900

Q36413746-1AEFC3CE-7EE5-4E5B-8019-DC8E2E84F3F2

Q36413746-2C2F664D-CA13-4963-9525-7A02C0E6793A

Q36413746-31464A60-3170-4C19-8480-188AE2B4671D

Q36413746-37910547-2D07-4EBA-A9EF-3331BB0F608C

Q36413746-3B0A8BFA-414D-4FE1-A534-EF373CB09583

Q36413746-4A48A559-0AE3-4456-8453-AB2F21F79BE4

Q36413746-4CF3ABD7-70E8-40FB-A51D-CD9A66117175

Q36413746-505FEEA8-1F00-4295-9CAC-C3FE11CC8907

P304

Q36413746-978DB64E-006F-4571-BEFE-465AA6A2916C

P31

Q36413746-48B7B08D-682E-410F-870C-568AF3EF11A5

P356

Q36413746-EEF59689-A9DC-48F7-8F2F-25E8E29AB8B9

P407

Q36413746-C48361C0-C510-4E04-9996-9583537E14F1

P433

Q36413746-5C5BA5CF-3FA0-4EDF-B62C-D4D034A28D32

P478

Q36413746-F6CF733F-A12F-45E1-B4A1-D7B59B5EF934

P50

Q36413746-47257D56-87FE-4C49-AC7B-FE377B6CDB36

Q36413746-6CF0EB57-DFE7-4661-BD3F-33D4655E29B4

Q36413746-F8A39D16-7EE9-4928-A84A-E669A11535D9

P577

Q36413746-3E3577FD-044D-4012-ABD1-C60F9AEA03FB

P5875

Q36413746-D973E802-18B8-454C-98E3-81276BE0CAF0

P698

Q36413746-634641AD-09C2-4C5E-B9B4-F49A5DD0C988

P921

Q36413746-5D7A9191-0057-4639-9BE4-1871B56B9CC4

P932

Q36413746-40876C37-D585-42E1-8646-D6FB3B0CDFD4

P356

ONCOTARGET.4583

P1433

P1476

TLR3 agonist and Sorafenib com ...... cellular carcinoma progression

@en

P2093

Jadegoud Yaligar

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Abastado

http://www.w3.org/2001/XMLSchema#string

Justin Lee

http://www.w3.org/2001/XMLSchema#string

Radoslaw Szmyd

http://www.w3.org/2001/XMLSchema#string

Tong Seng Lim

http://www.w3.org/2001/XMLSchema#string

Valerie Chew

http://www.w3.org/2001/XMLSchema#string

Victor Ho

http://www.w3.org/2001/XMLSchema#string

P2860

Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection

Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Sorafenib in advanced hepatocellular carcinoma

Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells.

Granzyme B: pro-apoptotic, antiviral and antitumor functions.

P304

27252-27266

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.4583

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Jeffrey D Steinberg

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281172412

http://www.w3.org/2001/XMLSchema#string

P698

26287667

http://www.w3.org/2001/XMLSchema#string

P921

Toll-like receptor

P932

4694987

http://www.w3.org/2001/XMLSchema#string